Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer

Rossella De Luca, Giuseppe Cicero, Livio Blasi, Massimiliano Alù, Valerio Gristina

Risultato della ricerca: Article

3 Citazioni (Scopus)

Abstract

Purpose: Pancreatic carcinoma is the neoplasia with the major mortality, and main standardtreatments in this cancer increase survival but do not lead to complete recovery of the patient.The aim of this study was to evaluate the efficacy of Abraxane® (nab-paclitaxel) in Italianpatients with metastatic pancreatic cancer (MPC).Patients and methods: We conducted a retrospective analysis of 80 patients. Overall survival(OS) was the primary end point for evaluating the efficacy of nab-paclitaxel in combinationwith gemcitabine treatment, while carbohydrate antigen 19-9 (CA 19-9) reduction, safety,progression-free survival (PFS), overall response rate and reduction in pain were secondaryend points.Results: The median OS was 8 months, and the median PFS was 5 months. A considerabledifference in CA 19-9 before and after treatment was observed. Descriptive and correlationanalyses were done to examine the relationship between CA 19-9 response and OS. Linearregression analysis between OS and CA 19-9 response revealed that CA 19-9 is an importantpredictor of OS, showing a positive correlation.Conclusion: Nab-paclitaxel is a well-tolerated and effective treatment for patients affected byMPC. The drug showed an improved tolerability profile, significant pain relief and an increasein survival rate.
Lingua originaleEnglish
pagine (da-a)1769-1775
Numero di pagine7
RivistaDrug Design, Development and Therapy
Volume12
Stato di pubblicazionePublished - 2018

Fingerprint

Pancreatic Neoplasms
Carbohydrates
Survival
Antigens
gemcitabine
Disease-Free Survival
Pain
130-nm albumin-bound paclitaxel
Neoplasms
Therapeutics
Survival Rate
Safety
Mortality
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cita questo

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer. / De Luca, Rossella; Cicero, Giuseppe; Blasi, Livio; Alù, Massimiliano; Gristina, Valerio.

In: Drug Design, Development and Therapy, Vol. 12, 2018, pag. 1769-1775.

Risultato della ricerca: Article

@article{9e203d3254664710b1559b8ed8050c7e,
title = "Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer",
abstract = "Purpose: Pancreatic carcinoma is the neoplasia with the major mortality, and main standardtreatments in this cancer increase survival but do not lead to complete recovery of the patient.The aim of this study was to evaluate the efficacy of Abraxane{\circledR} (nab-paclitaxel) in Italianpatients with metastatic pancreatic cancer (MPC).Patients and methods: We conducted a retrospective analysis of 80 patients. Overall survival(OS) was the primary end point for evaluating the efficacy of nab-paclitaxel in combinationwith gemcitabine treatment, while carbohydrate antigen 19-9 (CA 19-9) reduction, safety,progression-free survival (PFS), overall response rate and reduction in pain were secondaryend points.Results: The median OS was 8 months, and the median PFS was 5 months. A considerabledifference in CA 19-9 before and after treatment was observed. Descriptive and correlationanalyses were done to examine the relationship between CA 19-9 response and OS. Linearregression analysis between OS and CA 19-9 response revealed that CA 19-9 is an importantpredictor of OS, showing a positive correlation.Conclusion: Nab-paclitaxel is a well-tolerated and effective treatment for patients affected byMPC. The drug showed an improved tolerability profile, significant pain relief and an increasein survival rate.",
author = "{De Luca}, Rossella and Giuseppe Cicero and Livio Blasi and Massimiliano Al{\`u} and Valerio Gristina",
year = "2018",
language = "English",
volume = "12",
pages = "1769--1775",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer

AU - De Luca, Rossella

AU - Cicero, Giuseppe

AU - Blasi, Livio

AU - Alù, Massimiliano

AU - Gristina, Valerio

PY - 2018

Y1 - 2018

N2 - Purpose: Pancreatic carcinoma is the neoplasia with the major mortality, and main standardtreatments in this cancer increase survival but do not lead to complete recovery of the patient.The aim of this study was to evaluate the efficacy of Abraxane® (nab-paclitaxel) in Italianpatients with metastatic pancreatic cancer (MPC).Patients and methods: We conducted a retrospective analysis of 80 patients. Overall survival(OS) was the primary end point for evaluating the efficacy of nab-paclitaxel in combinationwith gemcitabine treatment, while carbohydrate antigen 19-9 (CA 19-9) reduction, safety,progression-free survival (PFS), overall response rate and reduction in pain were secondaryend points.Results: The median OS was 8 months, and the median PFS was 5 months. A considerabledifference in CA 19-9 before and after treatment was observed. Descriptive and correlationanalyses were done to examine the relationship between CA 19-9 response and OS. Linearregression analysis between OS and CA 19-9 response revealed that CA 19-9 is an importantpredictor of OS, showing a positive correlation.Conclusion: Nab-paclitaxel is a well-tolerated and effective treatment for patients affected byMPC. The drug showed an improved tolerability profile, significant pain relief and an increasein survival rate.

AB - Purpose: Pancreatic carcinoma is the neoplasia with the major mortality, and main standardtreatments in this cancer increase survival but do not lead to complete recovery of the patient.The aim of this study was to evaluate the efficacy of Abraxane® (nab-paclitaxel) in Italianpatients with metastatic pancreatic cancer (MPC).Patients and methods: We conducted a retrospective analysis of 80 patients. Overall survival(OS) was the primary end point for evaluating the efficacy of nab-paclitaxel in combinationwith gemcitabine treatment, while carbohydrate antigen 19-9 (CA 19-9) reduction, safety,progression-free survival (PFS), overall response rate and reduction in pain were secondaryend points.Results: The median OS was 8 months, and the median PFS was 5 months. A considerabledifference in CA 19-9 before and after treatment was observed. Descriptive and correlationanalyses were done to examine the relationship between CA 19-9 response and OS. Linearregression analysis between OS and CA 19-9 response revealed that CA 19-9 is an importantpredictor of OS, showing a positive correlation.Conclusion: Nab-paclitaxel is a well-tolerated and effective treatment for patients affected byMPC. The drug showed an improved tolerability profile, significant pain relief and an increasein survival rate.

UR - http://hdl.handle.net/10447/357831

M3 - Article

VL - 12

SP - 1769

EP - 1775

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -